Issue: BCMJ, vol. 56, No. 10, December 2014, Page 473 Editorials

A set of negative and often unfair beliefs that a society or group of people have about something. A mark of shame. (noun)

Even the word has an unpleasant ring to it.

I think methadone therapy is associated with stigma among physicians. Has this been aided and abetted by a lack of knowledge of methadone in clinical practice? Is it because addiction doesn’t really fit our definition of illness and we see it as a lifestyle choice? There are other conditions that stem from how we choose to live our lives, from lung cancer and smoking to diabetes and obesity. My guess is that sharing a diagnosis of cancer or diabetes, from a public perspective, is much easier than admitting to being on methadone. Many patients are not comfortable sharing that openly or confidentially, even with me when I see them in the emergency department.

A Cochrane review of methadone in 2009 clearly elucidated its benefits in decreasing the risk of contracting HIV, hepatitis B and C, and overdose death. Successful treatment usually requires long-term therapy to decrease illicit opioid use and manage dependence. Patients on methadone are more likely to stay in treatment programs and not relapse than those who are managed in a drug-free or abstinence program. There is a best individual dose for methadone and we know that less is not better. Patients on moderate doses are more likely to be compliant and avoid illicit opioids than those treated with low doses. All these positive advantages are in addition to methadone therapy being compatible with normal activities at work and school. It is hard to suggest this is unworthy or ill-conceived treatment for the medical illness of opioid addiction.

Perhaps, because therapy is aimed to control but not cure opioid addiction, physicians are less accepting of methadone therapy. Treatment itself causes drug dependence. However, there are many other examples of long-term therapy that are very successful in improving patients’ well-being without cure, from infliximab for rheumatoid arthritis to ramipril for congestive heart failure. But no stigma there.

My own perspective was significantly updated after a year on the College of Physicians and Surgeons of British Columbia’s Methadone Maintenance Committee. Previously, my sliver of knowledge consisted predominantly of methadone’s long half-life, toxic effects, and once-a-day dosing. What an eye-opening privilege to spend time with clinicians with extensive expertise in managing patients on methadone. They brought real-world practicality, compassion, and a deep awareness of the many challenges their patients face in addition to opioid dependence. These physicians showed me the breadth of complexity in providing care to these patients, and all without a sense of stigmatization. The focus was on how to provide the best care to a group of patients who are among the most challenging, diverse, and often vulnerable. Deft clinical acumen, sound knowledge of pharmacology and drug interactions, skill in psychiatry, social work, and maternal health—the list of medical topics covered when seeing a patient on methadone can be vast. It is not just about writing that special prescription for methadone—that makes up a minuscule part of the care process. Even with our many dedicated physicians, there are regions in BC that need more such skilled and authorized methadone prescribers. This shortage makes it harder for patients to get their care locally.

Across Canada there is now tremendous focus on the amount of opioid prescribing by physicians and the increasing numbers of patients with opioid dependence. While we have to address the root causes and be leaders in minimizing harm from opioids, it is essential that we manage dependence well. Methadone is a key piece to long-term care for opioid addiction. Shame and stigmatization are not concepts that should come to mind when we think about this treatment regimen.

Anne I. Clarke, MD. Stigma. BCMJ, Vol. 56, No. 10, December, 2014, Page(s) 473 - Editorials.

Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.

For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit

BCMJ Guidelines for Authors

Leave a Reply